Douglas G. McNeel: stay current reading research literature, there is no substitute for hard work!
Douglas G. McNeel: stay current reading research literature, there is no substitute for hard work!
Meet The Professor
The "Meet the Professor" series features interviews with the global Key Opinion Leaders, providing a window into the new developments, breakthroughs, and achievements in the interviewees’ professional fields, both clinically and academically.
ERAS and Tubeless—Michael Haddock: the past and future of proton beam
ERAS and Tubeless—Michael Haddock: the past and future of proton beam
Professor Norman Wolmark: perseverance sometimes pays off
Professor Norman Wolmark: perseverance sometimes pays off
Professor I. Craig Henderson: triple negative breast cancer is most chemo-sensitive of all subtypes of cancer
Professor I. Craig Henderson: triple negative breast cancer is most chemo-sensitive of all subtypes of cancer
Professor Charles M. Balch: higher sophistication and accuracy of clean data are important for sophisticated clinical trials
Professor Charles M. Balch: higher sophistication and accuracy of clean data are important for sophisticated clinical trials
Professor William J. Gradishar: individualized treatment scheme for breast cancer
Professor William J. Gradishar: individualized treatment scheme for breast cancer
Professor Charles E. Geyer: neoadjuvant therapy is becoming standard of care for HER2+ breast cancer
Professor Charles E. Geyer: neoadjuvant therapy is becoming standard of care for HER2+ breast cancer
Professor Bruce D. Minsky: Advances in radiation oncology in 2014 ASTRO
Professor Bruce D. Minsky: Advances in radiation oncology in 2014 ASTRO
Professor Hope S. Rugo: Reversing resistance and hormone therapy for metastatic breast cancer
Professor Hope S. Rugo: Reversing resistance and hormone therapy for metastatic breast cancer
Prof. Yi-Long Wu: Patients on the afatinib arm had a significantly better quality of life ac-cording to the data of LUX-Lung 6
Prof. Yi-Long Wu: Patients on the afatinib arm had a significantly better quality of life ac-cording to the data of LUX-Lung 6
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma
Professor Jon Wigginton: where we are standing in immunotherapy
Professor Jon Wigginton: where we are standing in immunotherapy
Charles M. Balch: specializing surgeons is going to be a trend
Dr. Charles M. Balch, M.D., FACS, Professor of Surgery, University of Texas Southwestern Medical Center, prior Deputy Director for Clinical Trials and Outcomes Research at Johns Hopkins Institute and Executive Vice President and Chief Executive Officer of American Society of Clinical Oncology (ASCO), enjoys a worldwide reputation for his distinguished career as a clinical and academic oncologist for the past 35 years and a leading authority in both melanoma and breast cancer.
Sandra M. Swain: follow your passion at work
Sandra M. Swain, MD, the current president of American Society of Clinical Oncology (ASCO), holds an international reputation as one of the America’s Leading Experts on Adjuvant Chemotherapy & Breast Cancer (Breast Neoplasm) and the leading authority both in the emergent field of inflammatory breast cancer treatment and in the treatment of early breast cancer with 28 years of medical experience and practice in Medical Oncology.
Prof. Peter Yu: opportunities and challenges in big data era
Dr. Peter Yu, the succeeding President of American Society of Clinical Oncology 2014-2015, is a Hematologist and Medical Oncologist at the Hematology-Oncology Department of the Palo Alto Medical Foundation and Director of Cancer Research.
Rik J Scheper: European Regulations on cell therapy, going too far?
Chinese Clinical Oncology (CCO) interviewed Dr. Rik, the immunologist and experimental pathologist in the Department of Pathology of VUmc in Amsterdam at the 2011 CSCO meeting in Beijing where he give us some comments on the regulations of cell therapy in Europe.
Managing clinical trial data-sharing databases: interview with Professor Daniel J. Sargent
Daniel J. Sargent, Ph.D., Professor of Oncology, Professor of Biostatistics and Director of Cancer Center Statistics of Mayo Clinic Cancer Center, Rochester, MN, USA, informed Chinese Clinical Oncology (CCO) of his past working experience related to clinical trials and databases collaboration like ACCENT and his project of the new co-authored column in CCO.
Prof. Shukui Qin: strategy on liver cancer treatment for Asian population
At the 16th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Prof. Shukui Qin, the executive member of ACOS and the chairman of CSCO, informed Chinese Clinical Oncology (CCO) of his professional view on Strategy on liver cancer treatment for Asian population.
Prof. Jean Armand: personalized medicine in France and the niche in future international cooperation
Jean-Pierre Armand MD, MSc, certified in Medical Oncology, is active as a senior consultant at Institute Gustave Roussy and Institute Curie in Paris.
Claus-Henning Koehne: the awareness of K-Ras is a great progress in molecular targeted therapy
Dr. Claus-Henning Koehne, Chairman of the Department of Hematology and Oncology, Klinikum Oldenburg, Germany, is an internationally renowned prolific and outstanding oncologist and hematologist.
| 1 - 20 of 20 Items |
Disclosure:
The series “Meet The Professor” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding.